Gan Gans got no mates, no girl friend , no money to buy MSB !...

First 8036 Last

Share
Profile

Follow
Cforry

13 Posts.

5

03/01/21

17:04

Post #: 49913857
Share

Originally posted by benelong: ↑

Well, I did say that I wouldn't say any more on this topic but that was before I read your latest.

I put a lot of time and effort into my original post. I welcome discussion and reasoned disagreement. I want to learn. But your misquotes of me and your non-sequiturs could be misleading to readers and wrongly detract from the information I try to provide and the sensible questions I welcome.
So I must answer, with apologies to those who might be bored.

I did say you were sub-literate. I didn't expect you to be so eager to prove it.

Example: "conspiracy". Look it up before you use it. A conspiracy requires two parties. So, I accused FDA and who else? Of what?
In fact, I acknowledged the FDA's reasons for rejecting the aGvHD application, without any argument from me. The fact is accepted, although MSB's continuing appeals are noted.
My point was that if Covid-ARDS results in secondary endpoints in a couple of months that are compelling of benefit in areas other than mortality then those post ODAC style reasons won't cut it with the people on the front line in hospitals, with politicians who are under the pump from the entire population for an answer to a problem that is tearing their nation apart. The powers that be will give a lot more credence to "We The People" than a small faceless team at the FDA.
I offered it as a discussion point. There's not a hint of conspiracy

Example: "obfuscation". Look it up. I said the FDA is "obfuscating" MSB?? And that's "textbook conspiracy theory"??? Which of my words accuse the FDA of obfuscating? You need a new textbook as well as a dictionary.

"Every single trial has failed in Mesoblasts history. You can’t argue with that. Yet, seemingly, you want to."

Nowhere have I denied that MSB's trials have failed to meet primary endpoints. I "seemingly" want to?? Show me one word that supports your gross mischaracterisation.

What I did say in my original post was that the Rem-L story in the Covid-ARDS trial is not over until the secondary endpoints are assessed. Please argue with that. I want that point discussed here.

It is confirmed by the FDA that sufficiently compelling secondary endpoints can count towards approval even when the primary endpoint is not met. Many of us hope that for the CHF DREAM trial. I am just offering this possibility for consideration in the ARDS trial. I welcome informed discussion. I certainly don't want to provoke further posts from people who for their own peculiar reasons (well, money, I suppose) try to dismiss well-meant contributions.

I don't have to answer you any more. The transparency of your motivations is plain to see. You want to discourage rather than inform. In fact, your posts are repetitious, boring and uninformative. I will not encourage you by engaging in further replies.

Expand

Gan Gans got no mates, no girl friend , no money to buy MSB ! Poor Gan Gans !

MSB Price at posting: $2.25 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

PME

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

ASX Market Update: Index pulls back from record highs | October 16, 2024

BM8

Battery Age Minerals gets set to capitalise on critical mineral demand

JBY

James Bay latest lithium player to pivot to other metals amidst lithium slump

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

There are more pages in this discussion • 10,283 more messages in this thread...

First 8036 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.38		Change -0.080(5.50%)		Mkt cap ! $1.569B

Open	High	Low	Value	Volume
$1.43	$1.43	$1.37	$5.321M	3.829M

Buyers (Bids)

No.	Vol.	Price($)
4	12214	$1.38

Sellers (Offers)

Price($)	Vol.	No.
$1.38	37660	5

View Market Depth

No.	Vol.	Price($)
4	12214	1.375
7	53796	1.370
7	53347	1.365
14	192096	1.360
3	45165	1.355

Price($)	Vol.	No.
1.380	37660	5
1.385	25000	1
1.390	56973	4
1.395	31284	2
1.400	146999	10

Last trade - 16.10pm 16/10/2024 (20 minute delay)

MSB (ASX) Chart

Gan Gans got no mates, no girl friend , no money to buy MSB !...

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

ASX Market Update: Index pulls back from record highs | October 16, 2024

Battery Age Minerals gets set to capitalise on critical mineral demand

James Bay latest lithium player to pivot to other metals amidst lithium slump

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Gan Gans got no mates, no girl friend , no money to buy MSB !...

Top Stories

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

ASX Market Update: Index pulls back from record highs | October 16, 2024

Battery Age Minerals gets set to capitalise on critical mineral demand

James Bay latest lithium player to pivot to other metals amidst lithium slump

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News